- Research article
- Open Access
- Open Peer Review
Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation
BMC Nephrology volume 19, Article number: 336 (2018)
There is a need for a large, contemporary, multi-centre series of measured glomerular filtration rates (mGFR) from healthy individuals to determine age- and gender-specific reference ranges for GFR. We aimed to address this and to use the ranges to provide age- and gender-specific advisory GFR thresholds considered acceptable for living kidney donation.
Individual-level data including pre-donation mGFR from 2974 prospective living kidney donors from 18 UK renal centres performed between 2003 and 2015 were amalgamated. Age- and gender-specific GFR reference ranges were determined by segmented multiple linear regression and presented as means ± two standard deviations.
Males had a higher GFR than females (92.0 vs 88.1 mL/min/1.73m2, P < 0.0001). Mean mGFR was 100 mL/min/1.73m2 until 35 years of age, following which there was a linear decline that was faster in females compared to males (7.7 vs 6.6 mL/min/1.73m2/decade, P = 0.013); 10.5% of individuals aged > 60 years had a GFR < 60 mL/min/1.73m2. The GFR ranges were used along with other published evidence to provide advisory age- and gender-specific GFR thresholds for living kidney donation.
These data suggest that GFR declines after 35 years of age, and the decline is faster in females. A significant proportion of the healthy population over 60 years of age have a GFR < 60 mL/min/1.73m2 which may have implications for the definition of chronic kidney disease. Age and gender differences in normal GFR can be used to determine advisory GFR thresholds for living kidney donation.
The glomerular filtration rate (GFR) is a standard measure of renal function and can be determined by measuring the clearance of a molecule freely filtered through the glomerulus (measured GFR, mGFR). Although urinary inulin clearance is the gold standard method for determining mGFR, measuring the plasma clearance of 51Cr-EDTA is less cumbersome to perform and provides comparatively accurate results . It is, therefore, the method used most commonly in the UK and throughout Europe, and is the technique recommended by the British Nuclear Medicine Society (BNMS) .
It is important to have accurate reference ranges for GFR. The current BNMS guideline quotes a reference range based on a series of mGFRs in 503 healthy subjects published in 1981: mean GFR in young adults was 105 mL/min/1.73 m2 which declined by 4 mL/min/1.73 m2 per decade up to 50 years of age, and 10 mL/min/1.73 m2 per decade thereafter [2, 3]. Similarly, in the largest study to date of mGFRs in a healthy population, which included 1057 prospective living kidney donors, mGFR declined by 4 mL/min/1.73 m2 per decade up to the age of 45 years, and 8 mL/min/1.73 m2 per decade thereafter . A single-centre cohort of 904 prospective living kidney donors found the decline in mGFR with age was nonlinear, getting steeper with age . Several studies have also reported gender to be a determinant of GFR [4, 6, 7]. It is important therefore that GFR reference ranges account for age and gender.
The purpose of this study was to use a large, contemporary, multi-centre series of mGFRs from healthy individuals to determine age- and gender-specific reference ranges. We also examined whether age and gender are determinants of GFR in a subgroup of individuals selected on the basis of having no evidence of kidney pathology. Further, we describe how our GFR reference ranges can be used to inform minimum thresholds of GFR considered safe for prospective living kidney donors to proceed to nephrectomy. This work formed the basis of new recommendations for the assessment of kidney function in the updated British Transplantation Society (BTS) guidelines on living donor kidney transplantation .
This was a retrospective study using routinely-collected health data. The study population comprised prospective living kidney donors from UK renal centres who had undergone mGFR as part of their evaluation and were included irrespective of whether or not they proceeded to donation. Prospective donors with significant co-morbidity are excluded before the stage of having mGFR and therefore our study population can reasonably be regarded as representative of the healthy population.
We used hospital databases to identify prospective kidney donors who had undergone mGFR in three renal centres: Queen Elizabeth Hospital, Birmingham, 2007–2014; Freeman Hospital, Newcastle upon Tyne, 2009–2015; and James Cook University Hospital, Middlesbrough, 2005–2015. All prospective donors with mGFR during these years were included, and patient records were used to extract individual age, gender, and mGFR. These data from our three centres were then amalgamated with individual-level data from a published study of mGFRs in prospective living kidney donors from 15 other UK renal centres  (measured between 2003 and 2010, although the years of measurement varied between centres, and completeness of capture for each centre is not known), producing a dataset of prospective donors from 18 centres with the following variables: age, sex, renal centre, and mGFR per 1.73 m2 body surface area (BSA).
All 18 centres adhered to the BNMS guidelines for the measurement of GFR . mGFR was determined by measuring the plasma clearance of a glomerular filtration tracer using the slope-intercept method with the Brochner-Mortensen correction applied . The tracer used was 51Cr-EDTA in our three centres and in all of the other 15 centres apart from one which used 99mTc-DTPA. The number of plasma samples obtained to calculate mGFR was two in our centres and varied between two to five in the 15 other centres. The Haycock formula, incorporating height and weight, was used to estimate BSA, and mGFR was scaled to 1.73m2 BSA .
Continuous variables are expressed as a mean and standard deviation. Reference ranges for GFR were created using segmented multiple linear regression incorporating the amalgamated data from all 18 centres to model mGFR as a function of age and gender. A normal probability plot was used to confirm the validity of the assumption that the residuals were from a Normal distribution. The upper and lower limits of the reference ranges were defined as two standard deviations (SD) above and below the mean, respectively. These ranges, in addition to other published evidence as described below, were used to establish GFR thresholds for prospective living kidney donors, below which kidney donation would not be recommended.
We identified a subgroup of prospective kidney donors from our three centres who had no proteinuria, normal renal imaging, and normal differential kidney function by collecting the following additional data from individual patient records: urine albumin-to-creatinine ratio (ACR) or protein-to-creatinine ratio (PCR), renal CT or MR imaging report, and differential kidney function by DMSA.
Prospective donors with any evidence of kidney pathology were excluded. Evidence of kidney pathology was defined as proteinuria (ACR ≥ 2.5 mg/mmol in males or ≥ 3.5 mg/mmol in females, or PCR ≥ 20 mg/mmol), abnormal renal imaging (other than angiomyolipoma, a few simple cysts, or a duplex system), or a > 10% difference in differential kidney function on DMSA. Those with missing data in any of these three variables were also excluded.
Data from the resultant subgroup of prospective living kidney donors with no evidence of kidney pathology were used to model mGFR as a function of age and gender as above.
Study population and GFR reference ranges
We identified and collected data for 1096 prospective living kidney donors from our three centres who had undergone mGFR between 2007 and 2015. These data were amalgamated with individual-level data from 1878 prospective donors from the 15 other UK renal centres, producing a dataset for 2974 prospective donors from 18 centres. 1284 (43.2%) were male, mean age was 46.3 years (SD 12.3), and mean mGFR was 89.8 mL/min/1.73m2 (SD 15.8). The cohort included 459 (15.4%) individuals over 60 years of age, 51 (1.7%) individuals over 70 years, and 1 (0.0%) individual over the age of 80 years. Figure 1 shows a scatter plot of mGFR by age. Overall, 78 (2.6%) individuals had a mGFR < 60 mL/min/1.73m2. Forty-eight (10.5%) of the 459 individuals aged over 60 years had a mGFR < 60 mL/min/1.73m2.
The means and reference ranges for GFR by age and gender are shown in Table 1 and Fig. 2. Overall males had a higher mGFR than females (92.0 vs 88.1 mL/min/1.73m2, P < 0.0001). Measured GFR was approximately 100 mL/min/1.73m2 until 35 years of age, following which there was a linear decline. This GFR decline was faster in females compared to males (7.7 vs 6.6 mL/min/1.73 m2/decade, P = 0.013). BSA did not correlate with age for males or females.
Subgroup of prospective donors with no evidence of kidney pathology
Of the 1096 prospective donors in our three centres, 220 (20.1%) were excluded as they had missing data in one or more of the three following variables: ACR or PCR, renal imaging report, or DMSA result. Of the remaining 876 individuals with a complete dataset, 155 (17.7%) were excluded as they had evidence of renal pathology: 82 (9.4%) had a > 10% difference in differential kidney function on DMSA, 67 (7.6%) had abnormal renal imaging, and 25 (2.9%) had proteinuria (these total 174 because 19 of the 155 excluded individuals had two abnormal variables). Therefore, 721 prospective donors from our three centres were included in the subgroup analysis and their baseline characteristics are presented in Additional file 1: Table S1. Mean age was 45.7 (SD 12.5) years and 323 (44.8%) were male. Mean mGFR in the subgroup was significantly higher compared to those excluded from our three centres (91.6 ± 14.4 vs 85.6 ± 14.0 mL/min/1.73m2, P < 0.001). As in the total cohort of prospective donors, mGFR in the subgroup declined with age and the GFR decline after 35 years of age was more rapid in females. In addition, males had a higher initial mGFR which showed a continuous linear decline, unlike females who had a lower initial mGFR that was stable until 35 years of age before a linear decline. Mean GFR ± two SDs for the subgroup are shown in Additional file 1: Table S2 and Figure S1.
Thresholds for living kidney donation
Age- and gender-specific mGFR thresholds, considered acceptable for prospective living kidney donors to proceed to nephrectomy, are shown in Table 2 and Additional file 1: Figure S2. We set a threshold mGFR of > 90 mL/min/1.73m2 for prospective donors younger than 30 years and a threshold of > 80 mL/min/1.73m2 for those aged 30–45 years. For those older than 45 years, the mGFR threshold was determined by calculating the lowest pre-donation mGFR that would leave the donor with a post-donation GFR within the reference range for their age and gender, assuming a 25% loss of GFR with donation. The rationale for these thresholds, which were determined based on our age- and gender-specific GFR reference ranges and previously published evidence, is discussed below.
This study is to the best of our knowledge the largest published series to date of mGFRs in a healthy population, and we have used it as the basis for new age- and gender-specific reference ranges for GFR and to define advisory mGFR thresholds for living kidney donation that form part of the updated BTS guidelines . In 2974 prospective living kidney donors from 18 UK centres, we found that young adults had an mGFR of approximately 100 mL/min/1.73m2 until 35 years of age, following which there was a linear decline that was faster in females. An age-related decline in GFR, which was faster in females, was confirmed in a subgroup of prospective donors selected on the basis of no proteinuria, normal renal imaging, and normal differential kidney function.
Ageing and GFR
Our finding that GFR is approximately 100 mL/min/1.73m2 in young adults is consistent with previously published data [3, 5, 12]. Published studies consistently show that GFR declines with age in healthy individuals, and it has been demonstrated that ageing is also associated with a decline in other physiological parameters, such as renal blood flow, and with structural changes such as a reduction in nephron number, glomerulosclerosis, and tubulointerstitial fibrosis [13,14,15].
Over 10% of prospective donors older than 60 years had a mGFR < 60 mL/min/1.73m2, and our model suggests that the lower limit of the normal range for GFR drops to 60 mL/min/1.73m2 by the age of 50 and 55 years for females and males, respectively, meeting the GFR cut-off in the current definition of chronic kidney disease (CKD) . Our age- and gender-specific GFR reference ranges may be useful in the management of an older individual with a GFR < 60 mL/min/1.73m2: if GFR is within their reference range and there is no other evidence of kidney disease, one may be more confident in attributing a GFR < 60 mL/min/1.73m2 to normal ageing rather than disease, which may help to avoid unnecessary investigation and over-medicalisation. A meta-analysis which evaluated the interaction of age on the association between creatinine-based eGFR and end-stage renal disease (ESRD) and mortality suggested that a low eGFR is associated with increased risks across all age groups, although the relative mortality risk associated with a reduced eGFR decreased with increasing age .
It should also be noted that men younger than 55 years and women younger than 50 years could have a GFR below the lower limit of their reference range but still ≥60 mL/min/1.73m2 and so, in the absence of another marker of renal disease, would be missed by the current definition of CKD. The available data on long-term outcomes is insufficient to know whether a young individual in this category is at an increased lifetime risk of adverse health outcomes.
The definition and diagnosis of CKD, particularly in the older population, is an area of ongoing debate, and a discourse on the use of a single GFR cut-off is beyond the scope of this paper. However, several reviews and opinion pieces have suggested that greater emphasis should be placed on age-related changes in GFR than current definitions of CKD allow for [12, 18, 19]. Our data showing that over 10% of healthy adults over 60 years of age have a GFR < 60 mL/min/1.73m2 could be used to support that position.
Gender and GFR
Although most studies have found no significant difference in GFR between males and females, our findings that males have a higher overall GFR and a less rapid decline with age are consistent with the results of several other reports [6, 20,21,22]. These findings were also evident in the subgroup of prospective donors with no evidence of kidney pathology.
Several theories have been proposed to explain the more rapid GFR decline seen in females. First, it has been proposed that females may have a higher GFR than males in young adulthood that is masked by scaling to BSA, which may lead to a faster rate of GFR decline similar to that seen in hyperfiltration-related renal pathology . Second, as females age, the impact of oestrogens on renal haemodynamics and structure are lost due to a gradual decline in oestrogen levels even before the menopause [23,24,25]. There is no evidence that this faster rate of decline in females is detrimental to health, and in the UK the prevalence of ESRD in women is actually lower than in men at all ages .
Minimum advisory GFR thresholds for living kidney donation
The evaluation of prospective living kidney donors aims to identify those whom donation would put at an unacceptably high risk of long-term complications, including ESRD. Previous studies have suggested that the risk of ESRD after living kidney donation is not higher than in the general population [27, 28], but there is a small absolute increased risk [29,30,31]. A recent meta-analysis found the relative risk for ESRD was about 9-fold higher in donors compared to non-donors, but the estimated incidence rate was less than 1 case per 1000 person-years . Assessment of GFR in prospective kidney donors is an important factor in determining risk and living kidney donation guidelines have provided threshold GFRs above which the increased risk may generally be considered acceptable. For example, the 2017 KDIGO guideline suggests that a GFR ≥90 mL/min/1.73m2 is acceptable for donation, while a GFR < 60 mL/min/1.73m2 is not acceptable for donation and a GFR 60–89 mL/min/1.73m2 may be acceptable depending on other risk factors .
We recommended an advisory threshold GFR of > 80 mL/min/1.73 m2 for prospective donors aged 30–45, because this appears safe based on long-term outcome studies showing only a very small absolute increased risk of ESRD in cohorts of donors with this level of renal function and in this age range [30, 31]. However, because these studies contained only small numbers of younger donors, and another study showed an increased absolute lifetime risk in younger donors with a GFR < 90 mL/min/1.73m2 , we have recommended an advisory threshold GFR of > 90 mL/min/1.73m2 for donors younger than 30 years of age.
For those over 45 years, we have recommended advisory GFR thresholds based on calculating the lowest pre-donation GFR that would leave the donor with a post-donation GFR within our age- and gender-specific GFR normal ranges, assuming a 25% loss of GFR [27, 35, 36]. Based on data showing that age-related GFR decline after donation appears to be slower than in the general population, donors should remain within the healthy reference range up to the age of 80 years [27, 35, 37]. Whilst it is acknowledged that these may be considered arbitrary thresholds, from first principles it would seem sensible to aim to keep GFR in the normal range. Our thresholds, unlike those in the KDIGO guideline, would also allow some older donors with a GFR < 60 mL/min/1.73m2 to donate.
In our study population of 2974 prospective donors, these GFR thresholds would lead to the exclusion of an additional 5.0% (19.9% vs 14.8%) of prospective donors compared to the thresholds in the previous BTS living kidney donation guidelines if adhered to rigidly .
However, whilst threshold GFRs provide useful guidance to clinicians assessing prospective living kidney donors, individualised decision-making is important, especially in cases where GFR may be just below the recommended advisory threshold, or where there are compounding risk factors for ESRD. This has recently been facilitated by the development of an online tool (www.transplantmodels.com/esrdrisk) which provides a 15-year and lifetime pre-donation risk of ESRD in prospective donors, which was based on a meta-analysis of data from nearly 5 million healthy individuals, similar to kidney donor candidates, from general population cohorts .
The strengths of this study include the large size of the cohort and the fact that it incorporates individuals from multiple centres which increases diversity and the generalisability of our reference ranges. However, we recognise that our study has some limitations. First, it is likely that there is some variation in practice between the 18 centres in conducting mGFRs. There was variation in the number of blood samples taken to calculate mGFR, one centre used a different glomerular filtration tracer, and there may have been variation in pre-procedure advice given to individuals, such as that pertaining to diet, medications, and fasting.
Second, our estimates of GFR in the general population may be biased by the use of prospective living kidney donors as our study population. Individuals who have volunteered to donate a kidney and have had a satisfactory initial medical assessment to reach the point of having their GFR measured are likely to be healthier than the unscreened general population, and we would therefore anticipate a higher reference range than in the general population. Conversely, many prospective kidney donors are related to the intended recipient with renal failure, and therefore the proportion of individuals in our study population with a family history of renal disease is almost certainly higher than in the general population. This may have resulted in a lower estimate of GFR than truly exists in the general population. We did not have data on donor-recipient relationship to examine this further. Another consequence of using prospective kidney donors was that there were relatively few individuals in the cohort over 70 years of age, and this is to be borne in mind when interpreting our GFR reference ranges in this age group.
Third, our data are cross-sectional rather than longitudinal. The change in GFR that we describe with age is the change in mean GFR at population level and does not necessarily describe the expected change in an individual’s GFR with ageing. Indeed, previous work has shown that there is considerable variation in GFR decline with age [14, 39].
Finally, we did not have ethnicity data, which would have allowed us to validate previous work which has suggested that individuals of Asian ethnicity have a lower GFR [20, 40, 41]. Whether or not ethnicity is a determinant of GFR is an important question which requires further study in large, ethnically diverse cohorts, with accurate measures of GFR.
A large multi-centre observational cohort study with prospective recruitment of potential living kidney donors, incorporating baseline and longitudinal demographic and bioclinical data with a standardized method for mGFR and other renal phenotyping would be desirable to provide robust data on the effects of age, gender, and ethnicity on GFR.
We have used a large multi-centre series of mGFR data from prospective living kidney donors to produce age- and gender-specific GFR reference ranges which have clinical utility during the assessment of potential living kidney donors and may have implications for the diagnosis of CKD in the general population.
British Nuclear Medicine Society
Body surface area
British Transplantation Society
Chronic kidney disease
Estimated glomerular filtration rate
End stage renal disease
Glomerular filtration rate
Kidney Disease Improving Global Outcomes
Measured glomerular filtration rate
Soveri I, Berg UB, Bjork J, Elinder CG, Grubb A, Mejare I, Sterner G, Back SE, Group SGR. Measuring GFR: a systematic review. Am J Kidney Dis. 2014;64(3):411–24.
Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS, British Nuclear Medicine S. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun. 2004;25(8):759–69.
Granerus G, Aurell M. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest. 1981;41(6):611–6.
Poggio ED, Rule AD, Tanchanco R, Arrigain S, Butler RS, Srinivas T, Stephany BR, Meyer KH, Nurko S, Fatica RA, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int. 2009;75(10):1079–87.
Blake GM, Sibley-Allen C, Hilton R, Burnapp L, Moghul MR, Goldsmith D. Glomerular filtration rate in prospective living kidney donors. Int Urol Nephrol. 2013;45(5):1445–52.
Smith HW. Comparative physiology of the kidney. In: Smith HW, editor. The kidney: structure and function in health and disease. New York: Oxford University Press; 1951. p. 520–74.
Wesson LG. Renal hemodynamics in physiologic states. In: Wesson LG, editor. Physiology of the human kidney. New York: Grune & Stratton; 1969. p. 96–108.
British Transplantation Society / Renal Association. Guidelines for living donor kidney transplantation. 4th ed; 2018.
Peters AM, Perry L, Hooker CA, Howard B, Neilly MD, Seshadri N, Sobnack R, Irwin A, Snelling H, Gruning T, et al. Extracellular fluid volume and glomerular filtration rate in 1878 healthy potential renal transplant donors: effects of age, gender, obesity and scaling. Nephrol Dial Transplant. 2012;27(4):1429–37.
Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest. 1972;30(3):271–4.
Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93(1):62–6.
Delanaye P, Schaeffner E, Ebert N, Cavalier E, Mariat C, Krzesinski JM, Moranne O. Normal reference values for glomerular filtration rate: what do we really know? Nephrol Dial Transplant. 2012;27(7):2664–72.
Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 2012;82(3):270–7.
Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302–7.
Rule AD, Amer H, Cornell LD, Taler SJ, Cosio FG, Kremers WK, Textor SC, Stegall MD. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010;152(9):561–7.
Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308(22):2349–60.
Delanaye P, Glassock RJ, Pottel H, Rule AD. An age-calibrated definition of chronic kidney disease: rationale and benefits. Clin Biochem Rev. 2016;37(1):17–26.
Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419–28.
Ma YC, Zuo L, Chen L, Su ZM, Meng S, Li JJ, Zhang CL, Wang HY. Distribution of measured GFR in apparently healthy Chinese adults. Am J Kidney Dis. 2010;56(2):420–1.
Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, Larson TS. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004;43(1):112–9.
Barnfield M, Burniston M. Reference data for Tc-99m-DTPA measurements of the GFR derived from live kidney donors. Nucl Med Commun. 2010;31:471.
Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab. 1976;42(4):629–36.
MacNaughton J, Banah M, McCloud P, Hee J, Burger H. Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol. 1992;36(4):339–45.
Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant. 2006;21(9):2577–82.
MacNeill SJ, Ford D. UK renal registry 19th annual report: chapter 2 UK renal replacement therapy prevalence in 2015: national and Centre-specific analyses. Nephron. 2017;137(Suppl. 1):45–72.
Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR, Matas AJ. Long-term consequences of kidney donation. N Engl J Med. 2009;360(5):459–69.
Cherikh WS, Young CJ, Kramer BF, Taranto SE, Randall HB, Fan PY. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transplant. 2011;11(8):1650–5.
Slinin Y, Brasure M, Eidman K, Bydash J, Maripuri S, Carlyle M, Ishani A, Wilt TJ. Long-term outcomes of living kidney donation. Transplantation. 2016;100(6):1371–86.
Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O, Reisaeter A, Pfeffer P, Jenssen T, Leivestad T, et al. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162–7.
Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL, Segev DL. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311(6):579–86.
O'Keeffe LM, Ramond A, Oliver-Williams C, Willeit P, Paige E, Trotter P, Evans J, Wadström J, Nicholson M, Collett D, et al. Mid- and long-term health risks in living kidney donors: a systematic review and meta-analysis. Ann Intern Med. 2018;168(4):276–84.
Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberu J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, et al. KDIGO clinical practice guideline on the evaluation and Care of Living Kidney Donors. Transplantation. 2017;101(8S Suppl 1):S1–S109.
Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, Chow EK, Kasiske BL, Kovesdy CP, Nadkarni GN, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374(5):411–21.
Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, Kumar R, Posselt AA, Pesavento TE, Rabb H, et al. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015;66(1):114–24.
Garg AX, Muirhead N, Knoll G, Yang RC, Prasad GV, Thiessen-Philbrook H, Rosas-Arellano MP, Housawi A, Boudville N, Donor Nephrectomy Outcomes Research N. Proteinuria and reduced kidney function in living kidney donors: a systematic review, meta-analysis, and meta-regression. Kidney Int. 2006;70(10):1801–10.
Lenihan CR, Busque S, Derby G, Blouch K, Myers BD, Tan JC. Longitudinal study of living kidney donor glomerular dynamics after nephrectomy. J Clin Invest. 2015;125(3):1311–8.
British Transplantation Society / Renal Association. United Kingdom guidelines for living donor kidney transplantation. 3rd ed; 2011.
Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. Age-adjusted standards for creatinine clearance. Ann Intern Med. 1976;84(5):567–9.
Barai S, Bandopadhayaya GP, Patel CD, Rathi M, Kumar R, Bhowmik D, Gambhir S, Singh NG, Malhotra A, Gupta KD. Do healthy potential kidney donors in India have an average glomerular filtration rate of 81.4 ml/min? Nephron Physiol. 2005;101(1):p21–6.
Jafar TH, Islam M, Jessani S, Bux R, Inker LA, Mariat C, Levey AS. Level and determinants of kidney function in a south Asian population in Pakistan. Am J Kidney Dis. 2011;58(5):764–72.
We would like to acknowledge Elsie Lanchbury and Chris Boivin from the Department of Nuclear Medicine, University Hospitals Birmingham NHS Foundation Trust, for their contributions to discussions and help with collecting data. We also acknowledge the 15 centres who provided data which was amalgamated into this study: Royal Sussex County Hospital, Royal Free Hospital, King’s College Hospital, Addenbrooke’s Hospital, Glasgow Royal Infirmary, Royal Liverpool University Hospital, St Bartholomew’s Hospital, St George’s Hospital, Derriford Hospital, Imperial College, London, Manchester Royal Infirmary, Canterbury Hospital, University Hospital, Coventry, St Mary’s Hospital, St James University Hospital.
No funding was obtained for this study.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study does not meet the Health Research Authority criteria for research requiring NHS REC approval and therefore ethics approval was not necessary. Patient consent was not necessary as the study involved the use of de-identified data.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Table S1. Characteristics of subgroup of prospective living kidney donors from three centres with no proteinuria, normal renal imaging, and normal differential kidney function (N = 721). Table S2. Measured GFR (mean ± 2 SD) by age and gender in a subgroup of prospective living donors from three centres selected on basis of no proteinuria, normal renal imaging, and normal differential kidney function (N = 721). Figure S1. Measured GFR (mean ± 2 SD) by age and gender in a subgroup of prospective living donors from three centres with no proteinuria, normal renal imaging, and normal differential kidney function (N = 721). Figure S2. Advisory age- and gender-specific threshold GFRs for prospective living kidney donors to proceed to nephrectomy for males (A, blue) and females (B, red). (DOCX 258 kb)